Alimera Sciences Inc. (ALIM)

5.14
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 5.14
Open 5.31
Day Low/High 5.11 / 5.31
52 Wk Low/High 0.00 / 18.15
Volume 14.26K
Avg Volume 605.40K
Exchange NASDAQ
Shares Outstanding 4.99M
Market Cap 25.37M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alimera Sciences Announces Board's Approval Of Reverse Stock Split Ratio

Alimera Sciences Announces Board's Approval Of Reverse Stock Split Ratio

ATLANTA, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc.

Alimera Sciences To Participate In The 10th Annual Craig-Hallum Alpha Select Conference In New York

Alimera Sciences To Participate In The 10th Annual Craig-Hallum Alpha Select Conference In New York

ATLANTA, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc.

Alimera Sciences Announces Third Quarter 2019 Financial Results And Provides Corporate Update

Alimera Sciences Announces Third Quarter 2019 Financial Results And Provides Corporate Update

Third Quarter and Recent Company Highlights: Consolidated Net Revenue Up 16% Compared to Third Quarter 2018 International Net Revenue Up 62% Compared to Third Quarter 2018 Launch of ILUVIEN ® for Non-Infectious Posterior Uveitis in U.

Alimera Sciences Announces Equity Purchase Agreement For Up To $20 Million With Lincoln Park Capital

Alimera Sciences Announces Equity Purchase Agreement For Up To $20 Million With Lincoln Park Capital

ATLANTA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc.

Alimera Sciences To Report Third Quarter 2019 Financial Results On Tuesday, October 29, 2019 And Provide Corporate Update

Alimera Sciences To Report Third Quarter 2019 Financial Results On Tuesday, October 29, 2019 And Provide Corporate Update

Conference Call to be held Wednesday, October 30, 2019 at 9:00am Eastern Time

Alimera Obtains Marketing Authorization For ILUVIEN® In Portugal For The Treatment Of Non-Infectious Posterior Uveitis

Alimera Obtains Marketing Authorization For ILUVIEN® In Portugal For The Treatment Of Non-Infectious Posterior Uveitis

Company continues strategy to grow the use of ILUVIEN internationally through geographic expansion and further penetration into existing markets

Alimera Sciences Announces Top Line Revenue Expectation For The Third Quarter Of 2019

Alimera Sciences Announces Top Line Revenue Expectation For The Third Quarter Of 2019

Consolidated net revenue expected to exceed $12.8 million

Alimera Sciences Announces Clinical Data Featuring The Benefits Of ILUVIEN® To Be Presented At The American Academy Of Ophthalmology Annual Meeting

Alimera Sciences Announces Clinical Data Featuring The Benefits Of ILUVIEN® To Be Presented At The American Academy Of Ophthalmology Annual Meeting

Data highlight ILUVIEN's advantages as the only therapy that consistently treats diabetic macular edema (DME) for up to 3 years

Alimera Announces Expansion Of Agreement With Distribution Partner Horus Pharma To Include Marketing ILUVIEN® In Benelux Countries

Alimera Announces Expansion Of Agreement With Distribution Partner Horus Pharma To Include Marketing ILUVIEN® In Benelux Countries

Following successful launch of ILUVIEN in France, Horus will bring the product to patients in Belgium, the Netherlands, and Luxembourg

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARES, HPR, IDCC, INS, IOR, RXN, TCI, TEO, TSU, VST, WMK Downgrades: ALIM, BBGI, CAG, CBM, CNDT, DEI, FNJN, NNBR, PENN Initiations: LOMA, NVMM Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AES, ALIM, APPS, EXAS, INVH, LBRDA, LBRDK, LLY, TLK Downgrades: CTT, DRH, HA, MTDR, ORIT, RNG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Elimination of liquidity covenants frees working capital to fuel company growth

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

20 electronic posters available for review as well

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Horus Pharma S.A.S. to also serve as agent in price negotiations with French Regulatory Authorities

TheStreet Quant Rating: D- (Sell)